What do systematic reviews say?

Antiplatelet agent vs placebo

Antiplatelet agent showed no clear difference in stroke‐related mortality (CT scan or MRI) compared with placebo (low certainty).

• Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes only
  RR 1.4 [0.54, 3.59]
  1 study · 372 participants
  Low

Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone

• Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 500 participants
  Very low

Standard‐dose VKA plus single antiplatelet agent vs vitamin K antagonist (VKA)

It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes all‐cause mortalitya compared with standard‐dose VKA (very low certainty).

• Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people… 2020 · Cochrane Headline outcomes only
  RR 0.49 [0.02, 11.68]
  1 study · 82 participants
  Very low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone

• Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 224 participants
  Very low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in mortality ‐ intermediate and long term compared with BMP plus placebo (moderate certainty).

• Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
  RR 0.48 [0.21, 1.06]
  3 studies · 649 participants
  Moderate